Invitrogen

Human CML66 (aa 349-442) Control Fragment Recombinant Protein

Name: Human CML66 (aa 349-442) Control Fragment Recombinant Protein
Brand: Invitrogen
SKU: RP-93769

Datasheet

Tech Support

Datasheet

Tech Support

Product Details

RP-93769

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

IKKNEGLTWPELVIGDKQGELIRDSAQCAAIAERLMHLTSEELNPNPDKEKPPCNAQELEECDIFFEESSSLCRFDGNTLKTTHVVNLGSNQYL

Tag

His-ABP-tag

Class

Recombinant

Type

Protein

Purity

>80% by SDS-PAGE and Coomassie blue staining

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

≥5.0 mg/mL

Purification

purified

Storage buffer

PBS/1M urea, pH 7.4

Contains

no preservative

Storage conditions

-20°C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

Product Specific Information

Highest antigen sequence indentity to the following orthologs: Mouse (93%), Rat (93%).

This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-54716. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.

Target Information

CML66, also known as TSGA10 (Testis Specific Gene A10), is a gene located on chromosome 8q23 that encodes a broadly immunogenic tumor antigen. The gene is expressed in various leukemias and solid tumors but has restricted expression in normal tissues, being predominantly found in the testis and heart. The physiological function of CML66 remains unclear. However, its immunogenic properties, including the ability to elicit strong humoral immune responses, make it a potential target for cancer immunotherapy. Studies have identified cytotoxic T lymphocyte (CTL) epitopes derived from CML66, suggesting that TSGA10-targeted therapies could be feasible. Moreover, research into the gene has revealed the existence of different isoforms, such as CML66-L (long) and CML66-S (short), which may have distinct roles in tumorigenesis and immune response modulation.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: Chronic myelogenous leukemia tumor antigen 66; NudC domain-containing protein 1; NUDCD1; Tumor antigen CML66